MedTrace Logo

Combination Chemotherapy and Interferon Alfa-2b in Treating Patients With Nonmetastatic Liver Cancer That Cannot Be Removed by Surgery

NCT00471484 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 54

Last updated 2011-06-22

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy, such as oxaliplatin, doxorubicin, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Interferon alfa may interfere with the growth of tumor cells. Giving combination chemotherapy together with interferon alfa may kill more tumor cells.

PURPOSE: This phase II trial is studying how well giving combination chemotherapy together with interferon alfa-2b works in treating patients with nonmetastatic liver cancer that cannot be removed by surgery.

Conditions

Interventions

BIOLOGICAL

recombinant interferon alfa-2b

DRUG

doxorubicin hydrochloride

DRUG

fluorouracil

DRUG

oxaliplatin

OTHER

diagnostic laboratory biomarker analysis

OTHER

immunoenzyme technique

OTHER

immunohistochemistry staining method

PROCEDURE

adjuvant therapy

PROCEDURE

biopsy

PROCEDURE

neoadjuvant therapy

PROCEDURE

therapeutic conventional surgery

Sponsors & Collaborators

  • National Cancer Centre, Singapore

    lead OTHER

Principal Investigators

  • Donald Poon, MD · National Cancer Centre, Singapore

  • Kian Fong Foo, MD · National Cancer Centre, Singapore

Study Design

Purpose
TREATMENT
Masking
NONE

Eligibility

Min Age
16 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-03-31

Countries

  • Singapore

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00471484 on ClinicalTrials.gov